Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s): DHTRF

Healthcare Biotechnology

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.

TSX:DHT.UN - Post by User

Dri Healthcare Trust

<< Previous

Bullboard Posts

Next >>

(6014)
•••

Comment by retiredcfon May 14, 2025 10:09am

35 Views

Post# 36573185

RE:RE:RBC Raises Target

Agreed. It never fails that you get several positive reports and suddenly the SP is in the red. Makes little sense but is a clear reason why you need to have a thick skin, a good sense of humour and lots of patience to prosper in these volatile markets. GLTA

<< Previous

Bullboard Posts

Next >>

A leap into the future of tokenized finance